Decreased phospholipase A2 activity in plasma and liver in uncontrolled diabetes mellitus. A defect in the early steps of prostaglandin synthesis?
- PMID: 3956877
- DOI: 10.2337/diab.35.4.403
Decreased phospholipase A2 activity in plasma and liver in uncontrolled diabetes mellitus. A defect in the early steps of prostaglandin synthesis?
Abstract
Arachidonic acid metabolites and prostaglandins participate in numerous physiologic functions. An enzyme important in the control of prostaglandin production is phospholipase A2. In this study, we have investigated the changes in plasma and hepatic phospholipase A2 activity in diabetes mellitus. In uncontrolled diabetic patients, the postheparin plasma phospholipase A2 level was 18.7 +/- 4.1 U/ml; this value was significantly different from the enzyme activities in control subjects (106 +/- 9.8 U/ml) and in controlled diabetic patients (87 +/- 7.3 U/ml). In the streptozocin-induced diabetic rat model, the postheparin plasma phospholipase A2 level (1.9 +/- 0.45 U/ml) was also decreased when compared with normal (9.4 +/- 1.6 U/ml) and controlled diabetic rats (7.0 +/- 1.3 U/ml). The total hepatic enzyme activity in the uncontrolled diabetic rats was only 21.6% of that seen in control rats. Subcellular fraction studies demonstrated that the enzyme activity is decreased in all fractions in the liver. Liver perfusion studies showed that the heparin-releasable phospholipase A2 activity in the perfusate was significantly decreased in the diabetic rats when compared with control and controlled diabetic animals. We conclude that postheparin plasma and hepatic phospholipase A2 activities are decreased in uncontrolled diabetes mellitus, that the low plasma activity is related to decreased release from the liver, and that the alterations in phospholipase A2 activity in plasma and liver are restored to normal by controlling the diabetic status.
Similar articles
-
Enhanced phospholipase A2 activity in rat plasma, liver, and intestinal mucosa following endotoxin treatment: a possible explanation for the protective effect of indomethacin in endotoxic shock.Metabolism. 1985 Feb;34(2):176-82. doi: 10.1016/0026-0495(85)90129-5. Metabolism. 1985. PMID: 3881649
-
Prostaglandins and cannabis--VIII. Elevation of phospholipase A2 activity by cannabinoids in whole cells and subcellular preparations.J Clin Pharmacol. 1981 Aug-Sep;21(S1):240S-248S. doi: 10.1002/j.1552-4604.1981.tb02601.x. J Clin Pharmacol. 1981. PMID: 6271829
-
Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats.Diabetes. 1988 Apr;37(4):429-35. doi: 10.2337/diab.37.4.429. Diabetes. 1988. PMID: 3132411
-
Gravidin: an endogenous inhibitor of phospholipase A2.Gen Pharmacol. 1993 Nov;24(6):1311-8. doi: 10.1016/0306-3623(93)90412-q. Gen Pharmacol. 1993. PMID: 8112500 Review.
-
Intracellular phospholipases A.Biochim Biophys Acta. 1980 Sep 30;604(2):191-246. doi: 10.1016/0005-2736(80)90574-x. Biochim Biophys Acta. 1980. PMID: 6252969 Review. No abstract available.
Cited by
-
Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action.Acta Diabetol. 1994 Dec;31(4):175-82. doi: 10.1007/BF00571947. Acta Diabetol. 1994. PMID: 7888687
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical